2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1874

Development of an Ultrasonographic Enthesitis Score for Psoriatic Arthritis Patients
Abstract Number: 1875

Assessment of Structural Damage of the Thumb Base in Patients with Hand Osteoarthritis: Comparing the Newly Developed Omeract Magnetic Resonance Imaging Scoring System with Standard Radiography
Abstract Number: 1876

A Non-Invasive Ultrasound Surface Wave Elastography Technique for Assessing Interstitial Lung Disease
Abstract Number: 1877

The Performance of MRI Using the 3D Volumetric Interpolated Breath-Hold Sequence (VIBE) Technique to Detect Structural Changes in Patients with Early Axial Spondyloarthritis in Comparison to Conventional Radiography and Computed Tomography
Abstract Number: 1878

The Utility of the Omeract Ultrasound Tenosynovitis Scoring System in Multicenter Clinical Trials
Abstract Number: 1879

Majority of Rheumatoid Arthritis Patients in Clinical Remission As Defined By DAS-28, CDAI, SDAI and RAPID-3 Have No Signal on Ultrasound Power Doppler
Abstract Number: 1880

Cancer Immunotherapy in Patients with Preexisting Rheumatologic Disease: The Mayo Clinic Experience
Abstract Number: 1881

The Utility of Autoimmune Serologies in Recurrent and Chronic Inflammatory Eye Disease
Abstract Number: 1882

Thymus and Activation-Regulated Chemokine (TARC) As Biomarker for IgG4-Related Disease
Abstract Number: 1883

Patterns of Osteoarticular Involvement in SAPHO Syndrome: A Cluster Analysis Based on Whole Body Bone Scintigraphy in 157 Patients
Abstract Number: 1884

Mepolizumab for the Treatment of Patients with Eosinophilic Granulomatosis with Polyangiitis: Post-Hoc Results of a Phase III Randomized, Placebo-Controlled Trial
Abstract Number: 1885

Epidemiology of Hospitalized Adult Onset Still’s Disease in United States
Abstract Number: 1886

Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis
Abstract Number: 1887

Ten-Year Continued Nonvertebral Fracture Reduction in Postmenopausal Osteoporosis with Denosumab Treatment
Abstract Number: 1888

Effect of Denosumab Compared with Risedronate on Percentage Change in Lumbar Spine Bone Mineral Density at 12 Months in Subgroups of Glucocorticoid-Treated Individuals

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].